Download free PDF
North America Automated Breast Ultrasound Systems Market - By Product, By End Use - Regional Forecast, 2025 - 2034
Report ID: GMI14842
|
Published Date: October 2025
|
Report Format: PDF
Download Free PDF
Authors: Mariam Faizullabhoy, Gauri Wani
Premium Report Details
Base Year: 2024
Companies covered: 15
Tables & Figures: 40
Countries covered: 2
Pages: 110
Download Free PDF
North America Automated Breast Ultrasound Systems Market
Get a free sample of this report
Get a free sample of this report North America Automated Breast Ultrasound Systems Market
Is your requirement urgent? Please give us your business email
for a speedy delivery!

North America Automated Breast Ultrasound Systems Market Size
The North America automated breast ultrasound systems market was valued at USD 846 million in 2024 and is projected to grow from USD 956.4 million in 2025 to USD 3.7 billion by 2034, expanding at a CAGR of 16.2%, according to the latest report published by Global Market Insights Inc. The market is experiencing significant growth, driven by several key factors, including the increasing prevalence of breast cancer in North America, rapid technological advancements in ABUS technology, and heightened awareness supported by favorable government initiatives.
Automated breast ultrasound (ABUS) offers advanced 3D imaging, significantly improving breast cancer detection, especially in women with dense breast tissue. Its growing adoption across hospitals, diagnostic centers, and breast care clinics in North America is due to its ability to enhance lesion visibility and diagnostic accuracy. Key players include GE Healthcare, Siemens Healthineers, Canon, Hologic, and SonoCine. Market innovations focus on automated scanning, consistent image acquisition, and enhanced diagnostic capabilities, aiming to improve patient outcomes and streamline screening workflows.
The market grew from USD 601.9 million in 2021 to USD 752.3 million in 2023. The growth of the North American ABUS market is driven by rising breast cancer rates, increased awareness of early detection, and supportive government screening initiatives. Adoption has accelerated due to advances in imaging technology, favorable regulations, and a shift toward personalized diagnostics. ABUS enhances lesion detection, offers operator-independent imaging, boosts diagnostic confidence, and provides a more comfortable, efficient screening experience.
The rising prevalence of breast cancer in North America is a key driver propelling the growth of the market. For instance, according to the National Breast Cancer Foundation, an estimated 316,950 new cases of breast cancer are expected to be diagnosed in the U.S. in 2025, representing approximately 15.5% of all new cancer cases. This underscores breast cancer’s continued status as the most common cancer among women. The increasing incidence is fueling demand for advanced screening technologies such as ABUS, particularly systems integrated with digital and AI capabilities that enhance screening efficiency, accuracy, and workflow optimization.
Further, growing awareness and supportive government initiatives are key factors driving the growth of the market. Prominent public health programs and organizations have played an important role in promoting education, advocacy, and regular screening, especially for women with dense breast tissue, where ABUS provides significant diagnostic advantages through high-resolution 3D imaging. For instance, initiatives such as the CDC’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which offers screening services to low-income women, and programs led by the National Cancer Institute have been instrumental in expanding access and encouraging early detection efforts.
ABUS is a specialized breast cancer screening technology for women with dense breast tissue, using a wide, automated transducer to capture standardized 3D images. Unlike handheld ultrasound, it reduces operator dependency and delivers consistent, high-resolution results for improved diagnostic accuracy.
15.2% market share
Collective market share in 2024 is Market Share 58.7%
North America Automated Breast Ultrasound Systems Market Trends
North America Automated Breast Ultrasound Systems Market Analysis
Based on the product, the North America automated breast ultrasound systems market is segmented into automated breast ultrasound system (ABUS), automated breast volume scanner (ABVS), and other products. The ABUS segment was valued at USD 538.6 million in 2024 and is projected to reach USD 2.4 billion by 2034, growing at a CAGR of 16.4%. In comparison, the ABVS segment, valued at USD 278.7 million in 2024, is expected to grow to USD 1.2 billion by 2034, at a CAGR of 15.9%.
Based on end use, the North America automated breast ultrasound systems market is segmented into hospitals, diagnostic imaging centers, and specialty centers. The diagnostic imaging centers accounted for the market share of 30% in 2024.
The U.S. automated breast ultrasound systems market was valued at USD 542.2 million and USD 604.3 million in 2021 and 2022, respectively. In 2024, the market size reached USD 758.3 million from USD 675.5 million in 2023.
Canada automated breast ultrasound systems market accounted for USD 87.6 million in 2024 and is anticipated to show lucrative growth over the forecast period.
North America Automated Breast Ultrasound Systems Market Share
North America Automated Breast Ultrasound Systems Market Companies
Few of the prominent players operating in the North America automated breast ultrasound systems industry include:
Hologic is a global medical technology company known for its advanced and clinically focused breast imaging solutions. In the field of automated breast ultrasound, Hologic offers the Aixplorer Series, which integrates UltraFast imaging and ShearWaveElastography to provide real-time, non-invasive assessment of tissue stiffness.
Canon leverages its deep expertise in imaging technology to deliver high-performance ultrasound solutions, including ABUS-compatible platforms. Canon ensures robust distribution and service capabilities. Its ABUS-compatible system, the Aplio i-series, integrates advanced beamforming and elastography technologies to support breast lesion characterization and workflow efficiency.
Philips maintains a competitive presence in the North America ABUS market through its diagnostic imaging systems and integrated informatics platforms. The company’s ABUS-compatible solution, the EPIQ Elite Ultrasound System, offers high-resolution imaging and AI-powered breast tissue analysis, tailored for dense breast screening.
North America Automated Breast Ultrasound Systems Industry News:
The North America automated breast ultrasound systems market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021-2034 for the following segments:
Click here to Buy Section of this Report
Market, By Product
Market, By End Use
The above information is provided for the following countries: